TNF and dermatomyositis: We therefore conducted an up-to-date systematic review regarding the new onset of DM/PM in patients treated with TNF-α blockers for different conditions and described the reports in regard to the patients characteristics and evaluated the role of autoantibodies, duration of therapy, and clinical picture when possible.